The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary; Does it also improve survival?

European Journal of Cancer

Volumn 54, Issue , 2016, Pages 159-162

  Prasad, Vinay ^a,c   Oseran, Andrew ^b   Fakhrejahani, Farhad ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MALE; NEOPLASMS, UNKNOWN PRIMARY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY;

CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; NEOPLASMS, UNKNOWN PRIMARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84956617326     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.09.006     Document Type: Note

References (18)

1. N. Pavlidis, and G. Pentheroudakis Cancer of unknown primary site: 20 questions to be answered Ann Oncol 21 2010 4
2. H. Carlson, R. Lenzi, M.N. Raber, and G.R. Varadhachary A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary Int J Clin Oncol 18 2 2013 6
3. K. Fizazi, F. Greco, N. Pavlidis, and G. Pentheroudakis Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 22 6 2011 5
4. N. Pavlidis, and G. Pentheroudakis Cancer of unkown primary Lancet 379 2012 8
5. J. Ross, K. Wang, L. Gay, G. Otto, and E. White Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies JAMA Oncol 1 1 2015 10
6. S. Kopetz, J. Desai, E. Chan, J. Hecht, P. O'Dwyer, and R. Lee PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors J Clin Oncol 28 15s 2010
7. A. Chen NCI-MPACT: molecular profiling-based assignment of cancer therapy for patients with advanced solid tumors 2013 National Cancer Institute Bethesda, Maryland
8. G.R. Varadhachary, T. Edmonston, S. Karanth, and H. Carlson Prospective gene signature study using microRNA to predict the tissue of origin (ToO) in pts with cancer of unknown primary site (CUP) J Clin Oncol 28 15s 2010
9. G. Varadhachary, D. Talantov, M. Raber, and C. Meng Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation J Clin Oncol 26 27 2008 7
10. J. Hainsworth, R. Pillai, W.D. Henner, and M. Halks-Miller Molecular tumor profiling in the diagnosis of patients with carcinoma of unknown primary site: retrospective evaluation of gene microarray assay J Mol Biomark Diagn 2 106 2011
11. F. Monzon, M. Lyons-Weiler, L. Buturovic, and C. Rigl Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin J Clin Oncol 27 15 2009 6
12. G. Varadhachary, and M. Raber Cancer of unknown primary site N Engl J Med 371 2014 9
13. H. Sacks, T. Chalmers Jr., and HS Randomized versus historical controls for clinical trials Am J Med 72 1982 8
14. S. Mailankody, and V. Prasad Five years of cancer drug approvals: innovation, efficacy, and costs JAMA Oncol 1 2015 2
15. K. Oien, and J. Dennis Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling Ann Oncol 23 2012 7
16. bioT3 Metastatic Cancer Solution, In: bioTheranostics Inc., editor: Web, bioTheranostics, Inc.; 2015. http://www.biotheranostics.com/about/biotheranostics/. [accessed 1.11.15]
17. V. Prasad, A. Vandross, C. Toomey, M. Cheung, and J. Rho A decade of reversal: an analysis of 146 contradicted medical practices Mayo Clin Proc 88 8 2013 9
18. K. Fizazi Trial comparing a strategy based on molecular analysis to the empiric strategy in patients with CUP (GEFCAPI04) 2013 Gustave Roussy